Seres Therapeutics Stock Target Price
| MCRB Stock | USD 0.73 0.08 9.88% |
Seres Therapeutics fundamentals help investors to digest information that contributes to Seres Therapeutics' financial success or failures. It also enables traders to predict the movement of Seres Stock. The fundamental analysis module provides a way to measure Seres Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Seres Therapeutics stock.
Seres |
Seres Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Seres Therapeutics' direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Seres Therapeutics could also be used in its relative valuation, which is a method of valuing Seres Therapeutics by comparing valuation metrics of similar companies.Seres Therapeutics is currently under evaluation in target price category among its peers.
Seres Fundamentals
| Return On Equity | -15.56 | ||||
| Return On Asset | -0.097 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.34) % | ||||
| Current Valuation | 165.75 M | ||||
| Shares Outstanding | 170.74 M | ||||
| Shares Owned By Insiders | 13.19 % | ||||
| Shares Owned By Institutions | 37.55 % | ||||
| Number Of Shares Shorted | 17.85 M | ||||
| Price To Earning | (4.04) X | ||||
| Price To Book | 5.81 X | ||||
| Price To Sales | 1.10 X | ||||
| Revenue | 126.33 M | ||||
| Gross Profit | (165.79 M) | ||||
| EBITDA | (85.43 M) | ||||
| Net Income | (113.72 M) | ||||
| Cash And Equivalents | 195.8 M | ||||
| Cash Per Share | 1.58 X | ||||
| Total Debt | 213.94 M | ||||
| Debt To Equity | 3.35 % | ||||
| Current Ratio | 2.35 X | ||||
| Book Value Per Share | 0.18 X | ||||
| Cash Flow From Operations | (117.35 M) | ||||
| Short Ratio | 5.75 X | ||||
| Earnings Per Share | (0.40) X | ||||
| Price To Earnings To Growth | (0.11) X | ||||
| Target Price | 3.87 | ||||
| Number Of Employees | 233 | ||||
| Beta | 2.05 | ||||
| Market Capitalization | 138.96 M | ||||
| Total Asset | 358.6 M | ||||
| Retained Earnings | (978.24 M) | ||||
| Working Capital | 76.75 M | ||||
| Current Asset | 207.61 M | ||||
| Current Liabilities | 10.92 M | ||||
| Net Asset | 358.6 M |
About Seres Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Seres Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Seres Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Seres Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:Check out Seres Therapeutics Piotroski F Score and Seres Therapeutics Altman Z Score analysis. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.